AzTrials
AzTrials

Diabetic WoundNCT07258381

Mailuo Shutong Pills for Diabetic Wound Healing: A Multicenter Randomized Trial

A study testing Mailuo Shutong Pills in people with Diabetic Wound and Chronic Wound Care, run by Peking University Third Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Mailuo Shutong Pills are a Chinese patent medicine approved for market release by the China Food and Drug Administration (CFDA) in 2009. It is formulated by integrating five classical herbal formulas, including Ermiao San, Simiao Yongan Tang, and Zhijing San. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Diabetic Wound, Chronic Wound Care
What is being tested?
Mailuo Shutong Pills
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
56 participants
Where
No sites listed yet
Study dates
1 Dec 2025to 1 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • a confirmed diagnosis of type 1 or type 2 diabetes mellitus;
  • the type of wound is an ulcer, with an ulcer area ranging from 1 to 40cm ²;
  • the wound etiology is diabetic, mainly abnormalities in blood glucose, resulting in poor or prolonged healing and requiring standard wound therapy;
  • The traditional Chinese medicine diagnosis is Damp-Heat Toxin Accumulation Syndrome;
  • voluntary participation in the study and signing of an informed consent form.

Who cannot join

  • Diagnosis of a Cold Pattern according to Traditional Chinese Medicine (TCM) differentiation, manifested as: pale, enlarged, and tender tongue with a white, moist or glossy coating; pallor; pale lips; aversion to cold with a preference for warmth; and loose stools.
  • Pregnancy or lactation.
  • Presence of severe, uncorrected systemic diseases, such as acute myocardial infarction, heart failure, hepatitis, shock, or respiratory failure.
  • Active bleeding within the wound that prevents the implementation of standard wound care.
  • Severe laboratory abnormalities: serum albumin < 20 g/L; hemoglobin < 60 g/L; or platelet count < 50 × 10⁹/L.
  • Diagnosis of advanced malignant tumor.
Show all 10Show fewer
  • Active phase of an autoimmune disease.
  • History of hypersensitivity to Mailuo Shutong Pills or Mailuo Shutong Granules.
  • Inability to cooperate with the study procedures or presence of psychiatric disorders.
  • Any other condition considered by the investigator as a clear, unmodifiable factor adversely affecting wound healing, making the candidate unsuitable for the study or unable to comply with the study requirements.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Long Zhang Executive Deputy Director, Medical Doctor contact

+86 010-82266699

longzh2000@163.com

About this study

Official title: A Multicenter, Randomized Controlled Trial on the Efficacy of Mailuo Shutong Pills in Treating Diabetic Wounds With Damp-Heat Toxin Accumulation Syndrome

Mailuo Shutong Pills are a Chinese patent medicine approved for market release by the China Food and Drug Administration (CFDA) in 2009. It is formulated by integrating five classical herbal formulas, including Ermiao San, Simiao Yongan Tang, and Zhijing San. Its composition is as follows: Honeysuckle Flower (Jinyinhua) serves as the principal component (Jun herb) for clearing heat and detoxifying; Astragalus Root (Huangqi) for tonifying qi, expelling toxin, and promoting diuresis; Phellodendron Bark (Huangbai), Atractylodes Rhizome (Cangzhu), and Coix Seed (Yiyiren) act as deputy components (Chen herbs) to clear heat and resolve dampness; Chinese Angelica (Danggui), Peony Root (Baishao), and Licorice Root (Gancao) alleviate spasm and pain; Figwort Root (Xuanshen) cools the blood, clears heat, drains fire, detoxifies, and softens hard masses. Leeches (Shuizhi), Centipede (Wugong), and Scorpion (Quanxie) serve as assistant components (Zuo herbs) to invigorate blood, resolve stasis, attack toxicity, dissipate nodules, and unblock collaterals to relieve pain. Licorice Root (Gancao) also harmonizes the various components in the formula as the envoy component (Shi herb). The complete formula possesses the effects of clearing heat and detoxifying, dissolving stasis and unblocking collaterals, and dispelling dampness and reducing swelling. It is indicated for various conditions differentiated in Traditional Chinese Medicine (TCM) as presenting with a pattern of dampness-heat and stasis obstruction, such as superficial thrombophlebitis and deep vein thrombosis in the non-acute stage.

Some studies suggest that Mailuo Shutong Pills may have a positive effect in the field of wound healing, for example, by significantly reducing the release of inflammatory mediators such as IL-1β, IL-6, CRP, and TNF-α caused by inflammatory diseases [11-13], and accelerating the healing of diabetic foot wounds [14]. Clinical guidelines, including the "Clinical Application Guide for Chinese Patent Medicines - Diabetes Volume" from the Diabetes Branch of the China Association of Chinese Medicine and the "Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Diabetic Foot" from the Chinese Medical Doctor Association, recommend Mailuo Shutong Pills for the treatment of diabetic foot ulcers [15]. However, the current related evidence-based medical evidence is insufficient. We have also observed that the adjunctive use of Mailuo Shutong Pills does not guarantee a shortened healing time for all patients with diabetic wounds. From a TCM perspective, the presence of a dampness-heat and stasis obstruction pattern is a key factor determining the efficacy of adjunctive Mailuo Shutong therapy. For Western medicine practitioners, tongue diagnosis presents a practicable factor for assessing pattern manifestation. Therefore, based on differences in patient patterns and using tongue appearance as an inclusion/exclusion criterion, to screen for the indications of Mailuo Shutong Pills combined with existing standard treatment for diabetic wounds constitutes an effective technical approach to address the aforementioned issues.

Consequently, this study aims to explore the indications for Mailuo Shutong Pills in diabetic wounds and obtain evidence-based medical evidence for its clinical efficacy within an integrated Chinese-Western medicine approach. Furthermore, to enhance the study's external validity and participant recruitment efficiency, thereby accelerating the research progress, this study is designed as an exploratory trial conducted across multiple centers.

Being tested
Mailuo Shutong Pills, Blank control
Keywords
diabetic wound, chronic wound care

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mailuo Shutong PillsDrug

    a medicine that treating Diabetic Wounds with Damp-Heat Toxin Accumulation Syndrome

  • Blank controlDrug

    Blank control

Study groups in NCT07258381
Study groupRoleWhat they receive
Experimental groupExperimentalBased on the clinical standard treatment plan, oral administration of Maoluo Shutong Pills was administered for 2 weeks
Receives: Drug: Mailuo Shutong Pills
Control groupSham comparatorthe clinical standard treatment plan
Receives: Drug: Blank control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. wound area reduction rate

    Pre-treatment area minus post-treatment area, then divided by pre-treatment area

    Measured: Day14 ± 2

Secondary outcomes (4)
  1. wound healing rate

    Percentage of healed wounds to total cases by D14

    Measured: Day14 ± 2

  2. Granulation tissue status

    They were classified as healthy granulation, inflammatory granulation, infected granulation, oedematous granulation, and aged granulation. D0/D14, wound granulation tissue status was recorded separately

    Measured: Day 0/Day 14 ± 2

  3. wound infection control

    0 points for no infection, 1 point for reduction of localised infection; 2 points for maintenance or exacerbation of localised infection; 3 points for disseminated infection; record D0/D14, the status of the wound infection and record the scoring results respectively

    Measured: Day 0/Day 14 ± 2

  4. Tongue appearance

    According to the tongue image photography SOP, record the tongue images

    Measured: Day 0, Day 7±2 and Day 14±2

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2025
  2. Study start1 Dec 2025 (estimated)
  3. Primary completion1 Dec 2026 (estimated)
  4. Study completion1 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized control trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
56 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07258381
Sponsor's protocol ID
Long2025-DW-ChineseMed:MLST
Status last verified
Nov 2025
First submitted
14 Nov 2025
Last updated
2 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Mailuo Shutong Pills in people with Diabetic Wound and Chronic Wound Care, run by Peking University Third Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Long Zhang Executive Deputy Director, Medical Doctor (+86 010-82266699, longzh2000@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

wound area reduction rate (time frame: Day14 ± 2). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in